SCHEMBL21769050

SCHEMBL21769050

CCOC(=O)c1nc(Cl)nc2nc(SC)sc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.49
ALDH1A1 P00352 5/20 0.40
CYP1A2 P05177 1/20 0.40
KDR P35968 1/20 0.38
GLP1R P43220 1/20 0.37
HSD17B10 Q99714 2/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 4/20 0.35
NPSR1 Q6W5P4 3/20 0.35
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.35
XBP1 P17861 1/20 0.35
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35
TLR9 Q9NR96 1/20 0.35
TARBP2 Q15633 1/20 0.34
HPGD P15428 2/20 0.34
TRPM8 Q7Z2W7 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21779999 0.84 KDR (0.38) LMNAKDR
SCHEMBL21768996 0.83 ALDH1A1 (0.43) LMNAALDH1A1CYP1A2GLP1RHSD17B10
SCHEMBL9296255 0.73 LMNA (0.70) LMNAALDH1A1CYP1A2HSD17B10GAA
SCHEMBL9296571 0.72 LMNA (0.61) LMNAALDH1A1CYP1A2GLP1RHSD17B10
SCHEMBL20489601 0.72 KDR (0.47) KDRNPSR1
SCHEMBL20489682 0.72 LMNA (0.47) LMNAALDH1A1CYP1A2HSD17B10GAA
SCHEMBL20489651 0.72 KDR (0.50) ALDH1A1KDRNPSR1KMT2A
SCHEMBL9115978 0.72 LMNA (0.64) LMNAALDH1A1CYP1A2HSD17B10GAA
SCHEMBL841384 0.72 LMNA (0.56) LMNAALDH1A1CYP1A2GLP1RHSD17B10
SCHEMBL7721609 0.72 LMNA (0.42) LMNAALDH1A1CYP1A2GLP1RHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200079793-A1 COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR CORVUS PHARMACEUTICALS, INC. 2020-03-12 US disclosed
EP-3616753-A1 COMPOUNDS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR Corvus Pharmaceuticals, Inc. (US) 2020-03-04 EP disclosed
EP-3616753-A1 COMPOUNDS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR Corvus Pharmaceuticals, Inc. (US) 2020-03-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200079793-A1 COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR ADORA2A, ADORA2B, ADORA3 LMNA 2401/4885ALDH1A1 769/4885CYP1A2 1029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.